A Phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

Journal:

American Journal of Obstetrics and Gynecology

Published:

2025-08-06

DOI:

10.1016/j.ajog.2025.07.040

Affiliations:

4

Authors:

6

Go to article

Institutions	Authors	Share
Thomas Jefferson University (TJU), United States of America (USA)	2.000000	0.33
SCYNEXIS, United States of America (USA)	2.000000	0.33
Cleveland Clinic, United States of America (USA)	1.000000	0.17
Wayne State University, United States of America (USA)	1.000000	0.17

Interested in Medical Microbiology?